Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We analyzed two distinct phenotypes of Schwann cells (SC), non-differentiated and differentiated, for their ability to produce IL-1alpha and IL-1beta, and to express message for IL-1 receptor antagonist (IL-IRA) and IL-1R type I, in vitro. SC were stimulated with:
lipopolysaccharide
(
LPS
), products of activated splenocytes (ASP), products from
LPS
stimulated SC (
SCP
), rat recombinant IL-1beta (rrIL-1beta) or dexamethasone. IL-1alpha, IL- 1beta and IL-1RA mRNA levels were highly upregulated after stimulation with
LPS
, ASP,
SCP
or rrIL-1beta. SC constitutively expressed low levels of message for IL-1alpha and IL-1beta but not IL-1RA. Specific mRNAs for both IL-1 isotypes were highly upregulated 2 to 4 h after
LPS
stimulation and then decreased and were undetectable by 24 h. IL-1RA mRNA was detectable after 6 h of
LPS
stimulation and was maximally upregulated at 24 h. IL-1 gene expression was inducible in both SC phenotypes. IL-1beta could be detected by immunofluorescence in SC, one to three days after
LPS
stimulation. At the same time IL-1 bioactivity was maximal in SC supernatants. Treatment with either
SCP
, rrIL-1beta or dexamethasone induced upregulation of IL-1R type I mRNA with maximal expression between 2 to 4 h, in SC. Inducible expression of genes for IL-1alpha, IL-1beta, IL-1RA and IL-1R type I in both differentiated and non-differentiated SC suggest autocrine and paracrine regulation of IL-1 by SC.
...
PMID:Induced upregulation of IL-1, IL-1RA and IL-1R type I gene expression by Schwann cells. 911 84
This study assessed whether combining adipose-derived mesenchymal stem cells (ADMSC) with preactivated, disaggregated shape-changed platelets (PreD-SCP) was superior to either therapy alone for protecting rat lung from acute respiratory distress syndrome (ARDS) complicated by sepsis. ARDS and sepsis were induced through 100% oxygen inhalation and peritoneal administration of 1.5 mg/kg
lipopolysaccharide
(
LPS
), respectively. Adult-male Sprague-Dawley rats (n=40) were randomized into sham-control (SC), ARDS-
LPS
, ARDS-
LPS
-ADMSC (1.2x10
6
cells), ARDS-
LPS
-PreD-
SCP
(3.0x10
8
, intravenous administration), and ARDS-
LPS
-ADMS/PreD-
SCP
groups, and were sacrificed 72 h after 48 h ARDS induction. Lung injury scores (LIS) and collagen deposition were highest in ARDS-
LPS
, lowest in SC, higher in ARDS-LPS+ADMSC than in ARDS-LPS+PreD-
SCP
and ARDS-LPS+ADMS/PreD-
SCP
, and higher in ARDS-LPS+PreD-
SCP
than in ARDS-LPS+ADMS/PreD-
SCP
(all p<0.0001). Alveolar-sac numbers, oxygen saturation, endothelial marker levels, and mitochondrial cytochrome-C levels exhibited opposite patterns with respect to LIS (all p<0.001). Levels of inflammatory, oxidative-stress, apoptosis, mitochondrial/DNA damage, and MAPK and Akt signaling markers exhibited patterns identical to that of LIS (all p<0.001). Anti-oxidant and anti-inflammatory protein levels increased progressively from SC to ARDS-LPS+ADMS/PreD-
SCP
(all p<0.0001). These findings indicate combined ADMSC/PreD-
SCP
was superior to either therapy alone for protecting rat lung from ARDS-sepsis injury.
...
PMID:Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets. 2913 74
